Investor Relations

Corporate ProfileNuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $14.00 + 0.06 (0.43%)
ExchangeNASDAQ
Volume234,149
Today's Open$14.00
Previous Close$13.94
Data as of 02/15/19 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $14.00 with a 52 week high of $25.17 and a 52 week low of $8.53.

Recent News

January 31, 2019

Nuvectra® Appoints Dr. Fred B. Parks as Chief Executive Officer

Elects Christopher G. Chavez as a Member of the Board of Directors PLANO, Texas, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks, PhD, as Chief Executive Officer, effective immediately. Dr. Parks has served as a member of the Company’s Board of Directors since March 2016 and will retain his position as a Director. His appointment follows Scott F. Drees’s decision to step down as

Read More >

January 29, 2019

Nuvectra Provides Update on Virtis™ FDA PMA Submission

PLANO, Texas, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has advised that its review of Company’s pre-market approval (PMA) application for its Virtis Sacral Neuromodulation (SNM) system has been extended beyond the expiration of the FDA’s 180-day review period. Scott Drees, Chief Executive Officer, commented, “FDA has informed us that they have

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
There are currently no events scheduled.